Drug intelligence / Profile preview

HLK-6005

Development stage: Preclinical
Lead developer: Shenzhen Yaoxin Biotechnology
Modality: Small Molecules

Overview

HLK-6005 is a small molecule drug candidate currently in preclinical development by Shenzhen Yaoxin Biotechnology (operating as Pharmacin) for the treatment of idiopathic pulmonary fibrosis (IPF). The compound was identified and optimized using the company's AI-driven drug discovery platform. HLK-6005 is intended to act as an anti-fibrotic agent to slow or reverse the progression of lung scarring in patients with IPF. As of August 2026, the program remains in the preclinical stage of development.

Beyond the preview

Go deeper on HLK-6005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-6005.

Explore the full profile